MIA
REGN icon

MainStreet Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

MainStreet Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$344K – 179
2022
Q3 		$344K Hold
500
– – 0.04% 138
2022
Q2 		$296K Buy
+500
New +$325K 0.03% 154
2020
Q2 		– Sell
-475
Closed -$232K – 285
2020
Q1 		$232K Buy
+475
New +$196K 0.03% 239

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MainStreet Investment Advisors's REGN Position: Q4 2022 in Review

MainStreet Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 500 shares — an estimated $344K sold.

MainStreet Investment Advisors first reported a position in REGN in Q1 2020 and held it in 3 quarters. The position peaked at $344K in Q3 2022. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • MainStreet Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • MainStreet Investment Advisors sold 500 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $344K.
  • MainStreet Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • MainStreet Investment Advisors's Regeneron Pharmaceuticals position peaked at $344K in Q3 2022.
  • 1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on MainStreet Investment Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.